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Abstract: Acute inflammation in response to stimuli such as infection can be of deleterious 
amplitude and/or duration in some individuals and often tends towards chronicity in older adults. 
This inflammatory pattern appears to be causally linked to higher all-cause mortality and other 
adverse outcomes such as frailty, sarcopenia, mood disorders and impaired cognitive function. 
Patients in this clinical state have a persistent pro-inflammatory cytokine profile. Exercise has been 
shown to shift baseline levels of tumor necrosis factor (TNF), interleukin-1 (IL-1) and other 
cytokines to a less inflamed setting, with interleukin-6 (IL-6) playing a key modulating role. Drugs 
can also modulate innate immune cells and their biochemical networks with a shift to a surveillance 
pattern. Theophylline and chloroquine are examples of drugs that could have clinical value as 
immune modulators. For example, theophylline induces a 20 percent fall in TNF and around 200 
percent increase in IL-10 production by blood-harvested mononuclear cells, and a fall of about 50 
percent in interferon-gamma (IF-γ) release. Pharmacological activity in that domain could be 
exploited in clinical practice, with the aim of establishing a less pro-inflammatory innate immune 
milieu after provocations such as infection, trauma or major surgery. 
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1. Introduction 
Physicians in a range of specialties recognize the need to improve collective knowledge of the 
role of persisting inflammation as an adverse prognostic factor in the context of acute illness. It is 
also increasingly understood that sustained and slowly resolving systemic inflammation is a 
contributing mechanism to chronic clinical states such as the frailty syndrome, physical 
deconditioning, sarcopenia, impaired cognition, low mood, poor functional performance and higher 
all-cause mortality. To some extent this pertains to people of all ages, though the brunt tends to fall 
mainly on elderly patients in whom inflammation can cause multiple clinical and functional 
difficulties. This review will consider the operation of sustained pro-inflammatory states in the 
causation of various disease phenotypes, using frailty and sarcopenia as the main examples. The role 
of physical exercise in the prevention and treatment of inflamed states will be considered, drawing 
on information selected from the large body of extant literature published in these areas of research. 
Further, the emerging potential for using a number of drugs to modulate inflammation will be 
examined, with particular attention to those that influence the balance of cytokines involved in the 
pro-inflammatory and anti-inflammatory signaling networks. 
2. Clinical considerations 
Physical deconditioning and frailty are now widely recognized as deleterious clinical states seen 
mainly but not exclusively in older people and those with chronic, usually inflammatory, conditions 
such as chronic obstructive pulmonary disease (COPD). It predisposes sufferers to a variety of 
problems with normal activities of daily living, particularly once the diminished physical reserves 
associated with ageing and chronic disease are further compromised by superimposed acute illnesses. 
Definitions of frailty vary, and though there is none that is universally accepted, a broad consensus is 
emerging that focuses on diminished strength, poor stamina, low mood and vulnerability to disease 
and injury [1]. Importantly in the context of this paper some features of the frailty syndrome are 
reversible, most importantly in the early stages and in the wake of acute events such as significant 
infections. Therefore, examples of the treatments that might ameliorate or reverse frailty will be a 
focus in this paper, with special reference to the probable mechanistic function of cytokines in that 
regard. 
3. Systemic inflammation, frailty and sarcopenia 
A number of studies have shown that systemic inflammation is likely to be causally associated 
with characteristic features of frailty, including loss of muscle mass and strength (sarcopenia) and 
poor appetite with weight loss (cachexia) [2–4]. The relationships between ageing, inflammation, 
exercise and muscle structure and performance are being progressively delineated and have been the 
subject of considerable recent attention in the scientific literature [2,5]. The molecular biology and 
chemical mechanisms of this pathogenic link are proving to be intricate and it has not been possible 
to date to propose a verifiable and unifying set of molecular mechanisms that can consistently 
describe all of the empirically recorded effects. The most likely explanation is that elements of the 
between-cell communication array controlling immune activity, such as cytokine signaling, the 
action of catecholamines, cortiso-steroids and other hormones, as well as more peripheral influences 
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such as complement activation, and interferon release influence one another in a way that can be best 
conceived as a multi-directional net with a web-like function and not as a collection of near-linear 
chemical reactions. Therefore, perturbation due to a noxious stimulus, or treatment intervention, in 
one part of the notional web causes alterations elsewhere in the network that are dependent upon 
variables with a large number of permutations, and consequently results in the appearance of 
inconsistency and unpredictability when studies are performed on subsets of the innate immune 
system or a very restricted suite of molecules. Therefore, it is reasonable to argue that it is likely to 
be impossible to discover generic pathways that describe and predict the precise immune-modulating 
effects of drug treatments or other interventions in all cases and circumstances. Effective treatments 
could therefore be the ones that result in wide corrective changes to the overall tension of the innate 
immune system, a phenomenon that is often called immune modulation, and through that mechanism 
lighten the inflammatory load that predisposes to frailty and other adverse clinical phenotypes. 
4. Persistent inflammation in later life 
At this stage, it is illustrative to take account of the operational condition of innate immune 
function in older age. Empirical research has shown that the baseline settings of chemical markers of 
inflammation, such as interleukin-1 (IL-1), tumor necrosis factor (TNF) and C-reactive protein (CRP) 
tend to be around 2 to 4 times higher in the plasma of elderly people, mainly but not exclusively in 
those over 80 years of age, in comparison with the plasma concentrations found in healthy younger 
volunteers [6,7]. In a study of adults with no overt illnesses the mean baseline peripheral plasma 
TNF level was 0.6 pg/mL in those age 29 years or less and 1.5 pg/mL in those age 69 years or more [6]. 
Further, a community study established the higher 95th centile for CRP to be age/50 and age/50 + 0.6 
for white men and women respectively. Similarly, the CRP distribution metrics for people of African 
heritage were age/30 and age/30 + 1.0 [8]. CRP can be conceived as a broad non-specific indicator of 
pro-inflammatory activity and the rise with age has been termed “inflammaging” by some 
researchers [7]. In many people the higher background inflammation can be explained by clinically 
obvious chronic inflammatory conditions such as chronic obstructive pulmonary disease (COPD) or 
rheumatoid arthritis (RA) [9]. Also, similarly elevated biochemical indices of inflammation have 
been described in older adults with various pathological states that appear to pull the innate immune 
setting from normal baseline in a pro-inflammatory direction. Important examples are central and 
visceral obesity, atheromatous arteritis, or diabetes type 2 [10–12]. Also pertinent to this review is the 
elevated pro-inflammatory state that often persists or resolves slowly after an acute inflammatory 
event, such as infection or trauma [13,14]. Elevated markers indicative of inflammation have been 
found with a high prevalence in Alzheimer’s disease (AD), chronic renal disease, osteoarthritis and 
physical inactivity [10,15–17]. Apparently well elderly people are sometimes found to have 
biochemical evidence of persistent low-level systemic inflammation with no apparent clinical cause, 
so old age therefore appears to be independently associated with a low-amplitude chronic 
inflammatory state in some individuals [7,18–20]. A large study of healthy volunteers living in the 
community found the mean plasma CRP to be 0.9 mcg/mL in young adults compared to 3.0 mcg/mL 
in people aged 65 years or more [18]. Baseline IL-6 and IL-1 also appear to correlate with age [20] 
though in some studies of healthy volunteers statistically significant correlation was not reached; 
some of the discrepancy might be due to participant selection criteria [21,22]. Persisting low-level 
inflammation appears to be linked with higher overall mortality [23,24], muscle weakness [25,26], 
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reduced daily living capability [24] and lower subjective perception of health [27]. The 
corresponding indicators of inflammation, such as CRP, IL-1, IL-6 and TNF tend to be found in 
varying proportions in different studies, depending to some extent on the exact laboratory methods 
deployed, but overall the detrimental effects outlined in earlier paragraphs were generally found in 
those with 1.5 to 3-fold elevation above the levels detected in well people of similar age. 
Comparative studies of the same type are lacking for young patients. 
From the pathogenic viewpoint it is important to take into consideration the evidence that 
chronic disease progression appears to be in part driven by a chronic inflammatory state and is not 
merely an indication of it [28], suggesting a complex mutually augmenting relationship between 
cause and consequence. Inflammation of the arterial endothelium, as observed in atherosclerotic 
disease is arguably the most well-defined example, and can be viewed as a template to understand 
the relationship between inflammation, ageing and pathology [29]. Further, it is apparent that a 
substantial proportion of older people have inflammatory biochemical responses to acute conditions, 
for example infection or trauma, that resolves more slowly than it does in younger adults [13,14]. 
The elevated blood levels of IL-1, IL-6 and TNF tend to be elevated longer and the corresponding 
increase in the anti-inflammatory cytokine interleukin-10 (IL-10) occurs later, is slower to rise and of 
lower amplitude. The empirical data that support this phenomenon have been consistently and 
unequivocally confirmed for pneumococcal and Gram-negative endotoxin antigens [30,31], in which 
cases the time taken to return to baseline in older people is approximately double that of young 
adults, despite comparable peak levels at the beginning of the episode. This suggests that in older 
subjects there is impaired anti-inflammatory regulation manifesting as a slower process to re-set the 
innate immune network to its surveillance baseline. That is likely to be a component mechanism 
leading to the more gradual physical and functional recovery often seen in old age, and might 
contribute to the tendency towards a chronically inflamed state.  
There are alternative explanations for chronic age-associated inflammation. For example, lower 
anti-oxidant capacity with a consequently higher vulnerability to oxidative stress [32]. Such a 
mechanism might contribute to a pro-inflammatory shift through inducing a higher density of 
toll-like receptors on a range of immunologically competent cells [33]. A case can consequently be 
constructed that teleologically links the elevated baseline inflammatory biochemistry in older age to 
appropriately increased anti-tumor immune vigilance or to unrecognized or asymptomatic 
auto-immune conditions. Similarly, there is not a proper understanding of the observation that 
cortisol and catecholamine concentrations tend to be elevated higher and with an extended duration 
after acute infection or trauma in older patients [34]. Whether that is solely in response to higher 
pro-inflammatory cytokine production or in part generated through other mechanisms determined by 
pituitary and adrenal activity is not known. Despite these uncertainties, the case for cytokines having 
a key regulatory role in the inflammatory phenotype associated with ageing is now in no doubt. 
5. Inflammation as a driver of pathology 
The perturbation of the inflammatory baseline setting and modulation described in the previous 
paragraph appears to play an important part in the pathogenesis of a number of several clinically 
important conditions in old age, including cardiovascular and cerebrovascular disease, metabolic 
syndrome, sarcopenia, neuronal dysfunction and some malignancies [9]. The effect on neuronal 
function tends to be insidious and is not fully understood, but the evidence that the tendency toward a 
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pro-inflammatory state and delayed or partial anti-inflammatory counter-regulation are contributory 
to acute and long-term cognitive impairment, depressed affect, illness behavior and autonomic 
dysfunction is persuasive. However, the recorded contribution of inflammation on the pattern of 
these clinical phenomena varies substantially depending upon sampling, assessment methods and 
clinical-pathological context [9]. 
Persisting low-amplitude elevation of CRP, mainly manufactured and secreted by hepatocytes in 
response to elevated IL-1, IL-6 and TNF, has been linked to an increased risk of vascular     
disease [29,35]. In that pathogenic setting CRP is probably best viewed as a marker for the elevated 
levels of the pro-inflammatory cytokines that are more directly implicated in the pathogenesis of 
vascular disease via their promotion of insulin resistance, dyslipidemia and inflammatory 
macrophage activity. Moreover, IL-1, IL-6 and TNF have been found to be reproducibly associated 
with such metabolic vectors of vascular pathology [36]. In later studies the pro-inflammatory 
cytokines interleukin-15 (IL-15), interleukin-18 (IL-18) and interleukin-8 (IL-8) were shown to be 
more specific risk factors for coronary artery disease, type 2 diabetes and some malignancies [37–39]. 
The neuro-pathological role of inflammatory cytokines is worthy of particular mention because 
of the burden of delirium and dementia to sufferers and those caring for them. Receptors for 
cytokines that augment inflammation are located on the cell membranes of most neurons [40] and 
supportive data are accumulating for the involvement of several chemokines, and other biochemicals 
with key roles in inflammatory responses, such as cortisol and adrenalin, in the regulation and 
control of nerve cell function. Receptors for a number of inflammatory chemokines are located not 
only on brain nerve cells but also on glial cells, including receptors for TNF, IL-1, IL-6 and 
interleukin-1 receptor antagonist (IL-1ra). Further, transport mechanisms located at the blood-brain 
barrier (BBB) have been found to facilitate the entry of certain cytokines into the cerebro-spinal  
fluid (CSF) and brain interstitium, including IL-1, TNF, IL-6 and IL-1ra, partly by transport of 
formed cytokines from plasma and partly by de novo synthesis and secretion on the CSF side of the 
BBB. In animal studies, it was found that quantifiable and consistent alteration in behavior patterns, 
such as appetite loss, hiding and drowsiness, can be caused by injecting physiological doses of IL-1 
and TNF [40–42]. These high-level neurological effects provide a pathway to a better appreciation of 
the cyto-chemical and structural mechanisms through which inflammation can alter high-level nerve 
function, including a mechanistic framework from which it might be possible to gain further insights 
into lethargy and delirium. A considerable volume of cognitive research has been focused on the 
dementias, particularly Alzheimer’s disease (AD) and related neurodegenerative conditions such as 
Parkinson’s Disease, and it has clearly been shown that the inflammatory state of individuals, 
including the modulation of cytokines, is altered in such patients but can be downregulated by 
regular exercise [15,43,44]. On the other hand, the part played by cytokines in the initiation and 
promulgation of the processes resulting in AD, or its rate and pattern of progression, is not so clear. 
The question still remains as to whether the raised CSF and plasma cytokine levels found in AD are a 
secondary consequence of a separate pathological process or a key factor in the pathogenesis of the 
disease. The observed protective properties of regular moderate-to-vigorous exercise on objective 
measures of cognitive performance indicate a real effect [43,44]. Inflammation also has an impact on 
other aspects of neurological function. For instance, there is evidence that the autonomic 
down-regulation, such as reduced vagal tone, consequent upon acute episodes of inflammation 
caused by illnesses such as lower respiratory tract infections or pyelonephritis, is partly mediated by 
cytokines, though other deconditioning mechanisms are probably involved [40]. The 
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down-regulation of cardiovascular sympathetic and parasympathetic reflexes is of particular interest 
in medical practice because that is an important factor in the causation of the postural hypotension, 
which can result in syncope and falls especially in older patients after acute illnesses, and is likely to 
a substantial degree to be a result of cytokine-induced sympathetic dysfunction [45]. Similar 
mechanisms are likely to contribute to the long-term autonomic dysfunction found in people with 
diseases characterized by chronic inflammation. The mechanisms whereby abnormalities of 
inflammation chemistry lead to dysfunction in sensory, motor and extrapyramidal systems are less 
well defined and likely to be a rewarding field for targeted research. 
6. IL-6 as an inflammation-modulating myokine 
IL-6 has tended to be regarded as a pro-inflammatory cytokine with a broad range of influences 
on the immune network that includes promoting the action of IL-1 and TNF, and as one of the key 
inducers of the insulin-resistant state often found in physically inactive people. Supporting this 
interpretation is the finding that plasma IL-6 concentrations become progressively elevated during 
the early phase of the response to acute pro-inflammatory stimuli, such as infection, and are 
frequently found to be raised above the normative level in patients with chronic inflammation, such 
as those with rheumatoid disease between acute episodes [46]. However, more recently it has 
become apparent that the function of IL-6 within the intricate web of influences that control innate 
immunity is considerably more subtle than its function as an acute phase chemokine. Under most 
physiological conditions the principal origin of IL-6 is active striated muscle and it is consequently 
referred to as a myokine in some classifications [47], though IL-6 is also synthesized and released by 
many other somatic cell types. Under exercise conditions, during and immediately after repetitive 
muscle action, IL-6 has been found to possess autocrine, paracrine and endocrine functional roles 
that mediate other metabolic effects, particularly insulin sensitization, on the contracting myocytes 
and other cells. Subtly, under those metabolic conditions IL-6 appears to stimulate the production 
and secretion of anti-inflammatory cytokines, particularly but not exclusively IL-10 [48]. Though the 
entire suite of actions of IL-6 on metabolic processes remains to be defined it clearly has an 
influence on the biochemistry of inflammation that is variable and conditionally dependent upon 
fluctuating metabolic settings with pleiotropic flexibility [47,48]. For example, under septic 
conditions IL-1 promulgates IL-6 and TNF though after exercise in a non-septic state IL-6 facilitates 
the release of the anti-inflammatory cytokines IL-10 and IL-1ra. This putative coordinating property 
of IL-6, a cytokine synthesized and secreted by actively contracting striated muscle, positions it as a 
key factor when considering the modulating influence of physical activity on inflammation and 
intermediate metabolism, and possibly posits the idea that IL-6 might be understood not simply as an 
regulatory chemokine but also in a hormone-like role with paracrine and autocrine functions [49]. A 
number of myokines with at least partially defined functions have been described but most have 
narrower biochemical roles than IL-6 and little or no controlling influence on setting the timing and 
amplitude of inflammatory chemical and cellular responses. The context-dependent and apparently 
broad-spectrum effects of IL-6 also signals the likelihood that one or more, as yet unrecognized, 
substances act as more proximal controllers, with the most likely site being intra-cellular or 
intra-nuclear and the most probable domain being epigenetic. Nevertheless, for the purposes of this 
paper IL-6 can be viewed as a cytokine that has an increasingly well-documented pleiotropic 
modulating role in immune system activity, with key functions in the re-setting of innate immune 
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baselines in response to physical activity. 
IL-6 rises in response to exercise at all ages [29,43,44,50,51]. In humans, this has been most 
thoroughly shown during concentric reciprocating exercise against a moderate resistance, such as 
running, though IL-6 is also produced by myocytes in response to eccentric muscle use and isometric 
contraction [52]. During normal movement the pattern of muscle contraction tends to be a 
changeable mixture of all these forms of muscle activity. The most definitive research has been 
conducted on young adult participants performing strenuous exercise regimens. In such studies, IL-6 
concentrations in plasma can rise by a factor of 100 or more above baseline levels, especially in 
response to moderate-severe exercise of long duration, for example distance running at the elite level, 
and similar responses have been demonstrated in animal studies conducted on mice [51,53]. A 
dose-response relationship between peak IL-6 amplitude and work rate, and duration, has been 
consistently demonstrated, particularly the latter. Measurable rises in blood IL-6 also occur in 
response to less strenuous forms of exercise, such as level-ground cycling or fast walking for    
10–20 minutes [54]. However, there have been no studies of the IL-6 response to very low work rates, 
for example slow walking for short distances, that is representative of the amount of physical work 
that can be achieved by many frail people. Interpreting the IL-6 response to muscle activity is 
rendered more complex by the baseline concentration fall that has been observed between repeated 
sessions of exercise separated by several hours [55]. In participants who take regular exercise it is 
reasonable to posit that the lower between-session baseline IL-6 levels are likely to be the critical 
anti-inflammatory outcome of muscle action, whereas the brief rise after exercise increases insulin 
sensitivity via a separate mechanism [56]. Further, the hormone-like influence of IL-6 on muscle 
cells also appears to be dependent on the physiological context and temporal profile of IL-6 secretion 
so that the steep rises after vigorous exercise seem to have a role in increasing muscle volume, 
contractility strength and stamina, therefore an anti-sarcopenic effect, while in contrast chronically 
raised baseline IL-6 concentrations probably contribute pathogenically to the degenerative changes 
that lead to muscle cell apoptosis and sarcopenia [50,57]. It might therefore be reasonable to 
hypothesize that the benefits of physical activity that appear to be mediated by IL-6 are the result of 
2 describable mechanisms. First, a broad-spectrum effect that dampens inflammation by stimulating 
the release of IL-10 and other anti-inflammatory cytokines that have a positive ameliorating 
influence on, for example, endothelial metabolism, insulin receptor function and liver protein 
synthesis. Second, more narrowly defined mechanisms through which the high but transient IL-6 
levels after exercise maintain muscle architecture and function and low between-exercise baseline 
concentrations reduce the drift to a sarcopenic phenotype, probably via complex gene-switching 
mechanisms that are currently not fully understood but have a profound influence on muscle cell 
metabolism and apoptosis [58–61]. 
7. The use of drugs to alter cytokine responses 
Under some clinical conditions it is not possible to utilize natural processes, such as 
spontaneous immune correction and exercise, to suppress inappropriately intense systemic 
inflammation, such as after severe trauma or during certain orthopedic treatments, when resistive 
exercises and regimens based on walking are not practical or are ruled out for clinical reasons. 
Similarly, for the majority of very sick or frail patients, including those with impairments for whom 
exercise-based treatment programs cannot be applied, it is impossible to achieve the work rates 
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required to obtain and sustain an immune-modulating effect. The same restrictions are also a factor 
for a large proportion of older patients as they recover from acute inflammation due to, for example, 
infection and trauma. Further, clinicians, particularly geriatricians, encounter many frail patients 
recovering from sepsis who are neither able nor willing to take part in attempts to regain basic 
mobility and feel unable to participate in a graduated exercise program. For such patients there is an 
imperative to consider deploying other methods to facilitate the re-setting of a normative baseline 
innate immune cytokine profile to try to mitigate the deleterious consequences of prolonged 
inflammation. Once aspects of nutrition, such as vitamin D status have been corrected as much as 
possible and the primary cause of the inflammation, for example pneumonia, has been adequately 
treated, and an exercise regimen is not possible, the next suite of interventions is pharmacological. 
However, it is important to emphasize that drugs must not be regarded as a substitute for the 
non-pharmacological interventions mentioned above, and a logical argument can be posited for the 
addition of immune-modulating drugs to treatments, such as physical activity and nutritional support, 
when that is a practical possibility. Drugs of many classes have been found to influence innate 
immune cell function and chemistry by shifting it to a less pro-inflammatory state. There is a 
substantial evidence base for benefit in chronic inflammatory states, though few studies of benefit in 
post-acute inflammation.  
8. Rationale for the therapeutic use of immune-modulating drugs 
From a practical perspective there is clearly a substantial tranche of patients who are unable to 
participate in exercise-based treatments to ameliorate inflammation, decrease the transition to 
sarcopenia or delay a lapse into an overtly frail condition in acute and chronic disease contexts. This 
review now proceeds with a discussion of the potential for drugs of several pharmacological classes 
to be used to shift patients’ innate immune state from a physiologically damaging inflammatory 
phenotype to a less detrimental surveillance setting. Because the immune modulatory effect of many 
drugs is not their primary therapeutic indication, most have not been studied to the extent that the 
precise anti-inflammatory mechanisms are thoroughly understood. Considering the complex net-like 
interactions between the cells, chemokines and other bio-chemicals involved in immune systems it is 
arguably inappropriate to try to depict such a system with the conventional model of linear reactions. 
Instead it is probably more informative to look at how some drugs seem to tug the immune web 
toward a more anti-inflammatory mode; a property that potentially could have usable therapeutic 
utility. In general, the evidence for a clinically beneficial effect is predicated on observational clinical 
studies, animal and cell culture experiments and clinical trials on a pilot scale. Full scale prospective 
clinical trials of good design are very few with the purpose of testing the efficacy of drugs in 
dampening the chronic inflammatory states leading to, for example, frailty and sarcopenia. 
Nevertheless, in some categories there is sufficiently strong evidence to advocate the careful use of 
some drugs outside their usual licensed indications for that purpose. To illustrate this potential this 
review will now consider in some detail the evidence for using methyl-xanthine drugs for their 
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9. Immune modulation by methyl-xanthines 
Theophylline, for many years primarily prescribed for treating airflow obstruction in patients 
with asthma and COPD, is now known to have several other pharmacological properties including 
an anti-inflammatory influence on innate immune responses. Its function as a bronchodilator is 
constrained by requirements to take account of a narrow therapeutic range (trough plasma level 
10–15 mg/L) that is close to the levels associated with significant symptoms of toxicity (>20 mg/L) 
so its therapeutic usefulness has been largely displaced by the better efficacy and less troublesome 
toxicity of beta-2 agonist and anti-muscarinic bronchodilators. However, some improved functional 
outcomes, for example timed mobility, took place in COPD sufferers receiving theophylline despite 
no measurable change in their lung function tests or arterial blood gas indices. More importantly, the 
apparent benefit remained present at low, usually non-toxic, (<10 mg/L) plasma concentrations [62]. 
Follow-up studies showed a local anti-inflammatory effect of theophylline on bronchial epithelium 
and sub-epithelial structures, at systemic level in vivo and on immune cells in vitro [62,63]. This 
appears to be a class effect as other methyl-xanthines, for example pentoxifylline, have a comparable 
effect [64] though the extant literature on this topic is more extensive for theophylline. A full 
biochemical understanding of the inflammation modulating characteristics of theophylline has yet to 
be elucidated, and it is likely to vary between individuals according to the prevailing pathological 
and physiological conditions. In an in vitro experiment it was found that a theophylline concentration 
of 15 mg/L lowered mean TNF production from 0.26 to 0.21 pg/mL (p < 0.05) by harvested monocytes 
and raised mean supernatant IL-10 from 0.35 to 0.98 pg/mL (p < 0.01). There was simultaneous 
reduction of the mean interferon-gamma (IFγ) level from 24.5 to 13.4 pg/mL (p < 0.05) [65]. In a 
similar manner, in vivo application of approximately equivalent levels of pentoxifylline over 4 days 
resulted in progressive decline in the production of pro-inflammatory cytokines (IL-6, IL-1, IL-8 and 
TNF) of the order of between 20 and 80 percent by harvested immune competent cells [64]. This 
phenomenon appears to act via epigenetic mechanisms involving induction of histone 
deacetylase-dependent gene switches that alter immune settings in the direction of a more 
anti-inflammatory phenotypic profile for immune cell activity, a mechanism that is independent of 
phosphodiesterase inhibition that is responsible for the bronchodilator action of methyl-xanthines 
such as theophylline [63,66]. Further, it has been found that theophylline also reduces baseline IL-6 
concentrations in peripheral blood in humans [67], but IL-6 appears to have a malleable function that 
depends on prevailing physiological and inflammatory conditions, as has been described in an earlier 
paragraph, so the therapeutic significance of this property is uncertain. Further, no empirical research 
has been conducted on the influence of theophylline or other methyl-xanthines on IL-6 production 
during and after exercise. However, from the existing evidence, taking into account the current state 
of understanding of epigenetic mechanisms, it is probable that theophylline induces a shift in the 
direction of an anti-inflammatory state through gene activation and deactivation in immune 
competent cells which are known to possess several gene switches that regulate the rate of synthesis 
of a number of cytokines [66,68,69]. Interestingly, a consistent finding has been that patients with 
COPD receiving theophylline in addition to their standard regimen have lower between-exacerbation 
baseline CRP levels, improved mobility and better scores on functional scales when compared with 
COPD control patients [70]. These apparently broad-spectrum effects of theophylline are a credible 
example of immune “modulation”, and it is particularly germane that theophylline given at standard 
bronchodilator doses also appears to suppress inflammation without lowering the essential protection 
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of timely and rapid innate immune responses to infection. Encouragingly, a well-designed study 
showed a lower mortality rate in patients with serious systemic infection given theophylline in an 
intensive care context [71,72]. From the patient safety perspective, it is important to note that the 
potentially beneficial anti-inflammatory effect has been found to occur at in vitro theophylline 
concentrations much lower than the plasma concentrations required for an optimal broncho-dilatator 
effect. A key study has shown that fibroblast IL-6 and IL-8 release was lowered by 25–30 percent at 
in vitro theophylline concentrations of 5 mg/L [73]. At such levels (5–10 mg/L) in vivo significant 
side effects or signs of theophylline toxicity are not usually encountered in clinical practice. 
Therefore, it is reasonable to advocate the short-term use of theophylline at low doses in an attempt 
to modulate inflammatory responses when they are extended beyond the beneficial phase after acute 
pro-inflammatory, typically after episodes of infection, particularly frail and physiologically 
vulnerable patients, when there are clinical and laboratory indicators of inappropriately prolonged 
inflammation and if they are not able to participate sufficiently in physical activity. By the same 
argument, there could be benefit conveyed by the extended use of theophylline to reduce chronic 
low-amplitude inflammation in an attempt to delay the onset and reduce the severity of long-term 
complications such as sarcopenia. To improve the evidence base in this therapeutic area there is 
clearly a need for well-designed research, including clinical trials, to ascertain the possible benefit of 
theophylline on certain key outcomes, such as mortality, muscle strength and cognition in patients 
with systemic inflammation of various patterns. In particular, properly conducted studies should be 
considered that explore the utility of low plasma concentration (5–10 mg/L) oral theophylline, as an 
adjunctive drug intervention for patients in the aftermath of septic illnesses or trauma to determine 
whether low-amplitude extended inflammation can be beneficially suppressed in such clinical 
settings. 
10. Examples of other immune-modulating drugs 
Though methyl-xanthines have been considered in detail above, drugs in other categories also 
alter innate inflammation chemistry. However, in many cases the side effects that occur at effective 
doses reduce their potential to be used as immune modulating agents. Some examples are briefly 
summarized below but the list is by no means exhaustive. 
Monoclonal antibodies (MCAs) now have an established position in the management of 
inflammatory disorders, with anti-TNF drugs, for example infliximab, being among the most widely 
applied examples. However, when deployed in an anti-inflammatory role MCAs are usually targeted 
to specific chemokines or their receptors [74] and thereby have a profound but narrow influence on 
certain immune functions. At normative doses MCAs also tend excessively to suppress some 
components of immune surveillance and consequently render patients vulnerable to unusual 
infections and some malignant neoplasms, particularly after long-term exposure to the drug. MCAs 
are costly, have to be administered parenterally and must be monitored closely for serious side 
effects, all of which limit their utility as subtle immune modulators. 
Corticosteroids have been used therapeutically for many years as drugs with generalized 
anti-inflammatory properties that can be exploited in a wide range of clinical conditions. They 
down-regulate pro-inflammatory immune cell synthetic and migratory activity, including cytokine 
release, but have a poorly defined influence on the re-establishment of the baseline equilibrium of a 
surveillance phenotype [75]. The broad immune dampening properties of corticosteroids is likely to 
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be the mechanism through which they convey, for example, benefit in severe forms of Covid-19 
pneumonia [76]. When used systemically, corticosteroids are limited by their mineralocorticoid 
effects (sodium and water retention), glucocorticoid effects (enhanced protein catabolism and 
glucose intolerance), tendency to disturb sleep and precipitate delirium, and increase the risk of some 
infections by lowering cell-mediated immune activity.  
Thalidomide and its analogues have been in use for many years as anti-inflammatory drugs for 
the treatment of mycobacterial diseases, particularly leprosy, and for the reduction of inflammation 
during chemotherapy for malignant neoplasms. Thalidomide appears to possess complex immune 
modifying activities including the lowering of pro-inflammatory cell activity and reducing IL-1, IL-6 
and TNF release [77,78]. This multi-point traction of the biochemical inflammatory milieu is 
comparable to that caused by methyl-xanthines. However, thalidomide is constrained by several 
important adverse effects at the doses normally prescribed, though diamino-diphenyl sulfone, an 
analogue of thalidomide, is better tolerated and was found to reduce indicators of sarcopenia, a 
frequent consequence of sustained systemic inflammation, in patients receiving it for the treatment of 
leprosy [79]. Further research targeted at that drug in a range of inflammatory states is clearly 
needed.  
Chloroquine and analogous 4-aminoquinoline drugs (4AQs) such as hydroxychloroquine and 
amodiaquine suppress the release of IL-1, IL-6, TNF and IFγ and promote the proliferation of 
immunologically active cells that produce IL-10 and IL-4 [80]. 4AQs have an established record as 
anti-inflammatory agents, particularly for the treatment of diseases with an auto-immune etiology, 
for example rheumatoid disease and systemic lupus erythematosus. The influence of 4AQs at low 
concentrations on cell behavior and cytokine chemistry has not been systematically researched and at 
normative treatment doses for inflammatory disorders, which are generally lower than the 
anti-malarial doses, many recipients experience significant adverse effects. However, 4AQs certainly 
warrant targeted research to define their potential role in the management of systemic post-infective 
inflammation [81]. 
Non-steroidal anti-inflammatory drugs (NSAIDs) reduce the clinical manifestations and 
biochemical indicators of localized and systemic inflammation and there are compelling data from a 
large credible study indicating that they have a preservative effect on muscle function in older age. 
The latter is most probably due to reduction of the pro-sarcopenic effect of pro-inflammatory 
cytokines [82]. NSAIDs are restricted, though not contraindicated, for prolonged courses of 
treatment by their clinically significant nephrotoxicity, interference with gastric mucosal protection 
and tendency to increase the risk of thrombosis.  
Beta-adrenergic receptor blockers (BBs) modify innate immune biochemical profiles, with a 
shift toward the anti-inflammatory phenotype. Propranolol has been studied most extensively in this 
regard but the effect is thought to be a class property of BBs [80]. This effect has largely been found 
with regard to the biochemical pattern of inflammation characteristic of chronic heart failure and 
arterial atherosclerosis [80,82]. The mode of action of BBs as anti-inflammatory drugs has not been 
fully delineated but is probably due to beta adreno-receptor blockade and the consequent fall in 
catecholamine-induced release of inflammatory chemokines by mononuclear cells. It can be argued 
that the lower overall mortality observed in patients receiving BBs for cardiac indications could be a 
consequence, at least in part, to suppression of systemic inflammation. 
Statins are now known to reduce systemic inflammation by a mechanism that is apparently 
independent of, and not dependent upon, the lowering effect on plasma lipids. The observed 
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reduction in the cellular and chemical manifestations of endothelial inflammation appears to be a 
result of suppression of a TNF-induced increase in reactive oxygen species in the vascular 
endothelium, but a non-specific systemic anti-inflammatory effect is also a contributary factor [83]. 
However, targeted research is lacking on the influence of statins on acute-phase or immediate 
post-acute inflammation due to stimuli such as sepsis and trauma. 
Metformin, and other biguanide drugs, have been shown to have anti-inflammatory properties, 
probably mediated as a result of a switch toward an anti-inflammatory phenotype by macrophages. 
No properly conducted intervention clinical trials have been carried out and the main key evidence 
derives from in vitro studies of endothelial function. However, it can be contended that the apparent 
improvement in cardiovascular outcomes observed in diabetic patients prescribed metformin are 
likely to be at least partly due to its anti-inflammatory properties [84,85]. There has been no research 
on the effect of metformin on acute inflammation or non-diabetic chronic inflammatory states. 
11. Conclusions 
There is a steadily rising degree of understanding of the relationship between systemic 
inflammation and the pathogenic pathways leading to of a range of acute and chronic illnesses, 
particularly when immune cells and cytokines express an inappropriately prolonged or intense 
pro-inflammatory phenotype. Regular moderate exercise improves a number of adverse 
consequences associated with inflammation. The most likely reason for this effect is the 
exercise-induced shift of the immune cellular and biochemical network to a less pro-inflammatory 
setting. IL-6 appears to have a key function in the modulation of innate immune chemistry toward a 
less deleterious baseline. Through this mechanism, and probably others, exercise is an important 
factor in preserving health during recovery from illnesses such as infections and trauma. Because 
some people are not able to achieve or sustain the work rates or keep up the exercise programs that 
lead to those benefits there is a need to look for alternative means of dampening dys-immune 
pro-inflammatory states. For that purpose, there is theoretical, laboratory, observational and some 
empirical clinical evidence that drugs with immune modulating properties, such as theophylline, 
could be used to reset innate immune cytokine dynamics, with potential health benefits. Logically, 
such drugs should also be considered as adjunctive treatments for patients who are able to participate 
in a therapeutic exercise regimen. Few of the candidate drugs are licensed for use as 
anti-inflammatory agents so there is a need for properly conducted trials to explore their therapeutic 
possible therapeutic utility. On reviewing these topics, it is apparent that we currently have an 
incomplete understanding of the control mechanisms that operate in the innate and adaptive immune 
systems, and even less knowledge of the interactions between the immune network, exercise and a 
wide variety of drugs. This is fertile ground for research which should be focused on illuminating the 
complex molecular biological chemistry of immune system control as well as the potential beneficial 
use of drugs to reset disordered immune cellular and chemical networks in a clinical context. 
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